Investing News NetworkOctober 11, 2024Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ('Cardiol' or the 'Company'), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the 'Common Shares') at a price to the public of US$1.60 per Common Share (the 'Offering Price') for gross proceeds of US$13.5 million (the 'Offering'), Canaccord Genuity has purchased an additional 1,265,625 Common Shares at the Offering Price pursuant to their exercise in full of the over-allotment option (the 'Over-Allotment Option'), for additional gross proceeds to the Company of $2,025,000 before deducting the underwriting commissions.After giving effect to the full exercise of the Over-Allotment Option, Cardiol sold 9,703,125 Common Shares under the Offering, for aggregate gross proceeds of US$15,525,000.The Company intends to use the net proceeds from the Offering to support the clinical development of CardiolRx for the treatment of recurrent pericarditis and for general and administrative expenses, working capital and other expenses.Canaccord Genuity acted as the sole bookrunner in connection with the Offering.The Offering was made pursuant to a U.S.

。在充分行使超额配售期权后，Cardiol在本次发行中出售了9703125股普通股，总收益为15525000美元。公司打算利用本次发行的净收益支持CardiolRx的临床开发，用于治疗复发性心包炎以及一般和管理费用、营运资金和其他费用。Canaccord Genuity担任此次发行的唯一账簿管理人。此次发行是根据美国。

registration statement on Form F-10, declared effective by the U.S. Securities and Exchange Commissions (the 'SEC') on July 16, 2024 (the 'Registration Statement'), and the Company's existing Canadian short form base shelf prospectus (the 'Base Prospectus') dated July 12, 2024. A preliminary prospectus supplement relating to the Offering was filed with the securities commission i.

美国证券交易委员会（“SEC”）于2024年7月16日宣布生效的表格F-10登记声明（“登记声明”），以及公司于2024年7月12日发布的现有加拿大简式基本架招股说明书（“基本招股说明书”）。与本次发行有关的初步招股说明书补充资料已提交给证券委员会一号。